Data cannot be shared publicly because of patient confidentiality under current Swedish legislation. Data are available from the Scandinavian Obesity Surgery Registry (contact via [www.ucr.uu.se/soreg/](http://www.ucr.uu.se/soreg/)) for researchers who meet the criteria for access to confidential data.

Introduction {#sec007}
============

Since 1980, the average body mass index (BMI) has risen globally, yielding a prevalence of obesity as high as 10.8% in men and 14.9% in women \[[@pmed.1002985.ref001],[@pmed.1002985.ref002]\]. In several countries, the prevalence may approach or even reach beyond 50% of the adult population \[[@pmed.1002985.ref003]\]. Obesity is a strong risk factor for developing type 2 diabetes (T2D) \[[@pmed.1002985.ref004]\]. Consequently, T2D contributes greatly to the overall burden of disease \[[@pmed.1002985.ref005]\]. Compared to nonsurgical treatment, bariatric surgery provides a more effective way to achieve long-term weight loss in obese individuals \[[@pmed.1002985.ref006]\], and increases overall survival in this patient group \[[@pmed.1002985.ref006]\]. Obese patients with T2D have a good chance of achieving long-term T2D remission after surgery \[[@pmed.1002985.ref007]--[@pmed.1002985.ref011]\], although some patients who initially remit later relapse \[[@pmed.1002985.ref007],[@pmed.1002985.ref012]\]. The duration of diabetes prior to surgery, glycemic control, insulin use, age, and postoperative weight loss have previously been suggested as factors influencing the chance of achieving remission of T2D after bariatric surgery \[[@pmed.1002985.ref009],[@pmed.1002985.ref011]--[@pmed.1002985.ref016]\]. These studies generally comprise small samples, some over rather short periods of time. Larger studies are thus needed to ascertain which factors are associated with diabetes remission.

The aim of the present study was to evaluate the impact of preoperative duration of diabetes and other factors on the chance of achieving diabetes remission after bariatric surgery.

Methods {#sec008}
=======

This study was a retrospective cohort study on prospectively collected data from the Scandinavian Obesity Surgery Registry (SOReg). The registry was launched in 2007 and covers virtually all bariatric surgical procedures in Sweden, with very high registration validity \[[@pmed.1002985.ref017]\]. All patients who received primary gastric bypass or sleeve gastrectomy surgery between January 1, 2007, and December 31, 2015, and registered in SOReg were considered for inclusion in the study. Only patients with T2D as defined by the American Diabetes Association were included \[[@pmed.1002985.ref004]\]. Although an original study plan was decided on by the authors, it was not documented beforehand. After the study began, percentage total weight loss (%TWL) was changed to percentage excess BMI loss (%EBMIL) in the multivariable analysis as a response to review; no other changes were made to the original plan.

By using the Swedish personal identification number, unique to each citizen, the SOReg data file was linked to the Swedish National Patient Register, the Swedish Population Register (for mortality data), the Swedish Prescribed Drug Register, and Statistics Sweden. Information on baseline characteristics, surgery, and follow-up were based on data from SOReg. Since cardiovascular comorbidity and previous pulmonary embolus/deep venous thrombosis are not obligatory variables in SOReg, data on these conditions were based on combined data from the Swedish National Patient Register and SOReg. Preoperative duration of diabetes was based on a combination of data from SOReg, the National Patient Registries and the Swedish Prescribed Drug Register. Data on specific pharmaceutical treatment for diabetes were based on data from SOReg and the Swedish Prescribed Drug Register. Information on education was based on patient-specific data from Statistics Sweden.

Procedures {#sec009}
----------

The surgical method for gastric bypass is highly standardized in Sweden, with 99% being an antecolic/antegastric gastric bypass procedure with a small gastric pouch \[[@pmed.1002985.ref018]\]. The sleeve gastrectomy is less standardized, but routinely performed using a 32--36 Fr bougie with the gastric division starting 5 cm from the pylorus and ending 1 cm from the angle of His. Perioperative care closely follows the Enhanced Recovery After Surgery guidelines, with early mobilization, routine thromboprophylaxis, and start of oral fluids on the day of surgery \[[@pmed.1002985.ref019]\].

Outcomes and definitions {#sec010}
------------------------

The main outcome was remission of diabetes 2 and 5 years after surgery. To allow comparison with previous studies, this was defined both as being without medication at these points in time (including a time frame of ±6 months) and achieving complete remission of diabetes.

Complete remission of diabetes was defined as a glycosylated hemoglobin A1c (HbA1c) \< 42 mmol/mol (6.0%) without medical treatment. Partial remission of diabetes was defined as HbA1c of 42--48 mmol/mol (6.0%--6.5%) without medical treatment, in accordance with the recommendations of the American Society for Metabolic and Bariatric Surgery \[[@pmed.1002985.ref020]\]. Controlled diabetes was defined as HbA1c \< 48 mmol/mol (\<6.5%) with medical treatment.

Comorbidity was defined as a medical condition requiring pharmaceutical treatment, or continuous positive airway pressure treatment in the case of sleep apnea. Cardiovascular comorbidity was defined as a history of ischemic heart disease, angina pectoris, cardiomyopathy, cardiac failure, or arrhythmic heart disease.

Postoperative weight loss was presented as change in BMI (ΔBMI = initial BMI − postoperative BMI), percentage total weight loss (%TWL = 100 × weight loss/preoperative weight), and percentage excess BMI loss (%EBMIL = 100 × \[initial BMI − postoperative BMI\]/\[initial BMI − 25\]). Postoperative complications were classified according to the Clavien--Dindo classification, and having a postoperative complication was defined as Clavien--Dindo ≥ 1. Postoperative complications graded ≥3b were considered serious complications \[[@pmed.1002985.ref021]\]. Since more specific classification of postoperative complications was made obligatory in SOReg starting January 1, 2010, only patients operated on from this date onwards were included in the analysis of serious postoperative complications.

Statistics {#sec011}
----------

Baseline data (before surgery) and follow-up data are presented as numbers of individuals (*n*) with percentages of patients for categorical values, mean ± standard deviation (SD) for continuous variables assuming normal distribution, and median ± interquartile range (IQR) for continuous variables not assuming normal distribution. Univariable logistic regression analyses were conducted to evaluate risks related to the major endpoints of the study. The correlation between diabetes duration and remission of diabetes was evaluated using the Spearman correlation test. Based on previous studies and plausible impact of preoperatively available factors, diabetes duration, insulin treatment, BMI, age, sex, HbA1c, education, %EBMIL, and surgical method were incorporated in the multivariable logistic regression analyses \[[@pmed.1002985.ref022],[@pmed.1002985.ref023]\]. Missing data were handled by listwise deletion. *p* \< 0.05 was considered to represent statistical significance.

SPSS Statistics version 25 (IBM, Armonk, New York, US) was used for all analyses.

Ethics {#sec012}
------

The study was approved by the Regional Ethics Committee in Stockholm (Dnr 2013/535-31/5, 2014/1639-32, and 2017/857-32) and conducted in accordance with the ethical standards of the 1964 Helsinki Declaration and its later amendments. No written consent was obtained from the study participants. However, in accordance with Swedish legislation, all participants were informed of the research and quality registry and that the data would be used in clinical research, giving the patients the right to decline participation.

Results {#sec013}
=======

During the inclusion period, 8,546 patients with T2D according to the definition of the American Diabetes Association were identified in SOReg. Two years after surgery, 57 patients had died, leaving 8,489 (99%) patients available for analysis of pharmaceutical usage. After exclusion of patients who died prior to the 5-year follow-up (*n =* 178) and patients who did not reach this time point by the end of the study (*n =* 2,980), 5,388 patients were available for analyses on pharmaceutical use at 5 years. HbA1c was available at 2 years for 3,594 patients (42% of patients reaching the 2-year follow-up) and at 5 years for 1,460 patients (27% of patients reaching the 5-year follow-up). Follow-up data on day 30 were available for 8,448 patients (99% of all patients) ([Fig 1](#pmed.1002985.g001){ref-type="fig"}). Data on baseline characteristics for the study group are presented in [Table 1](#pmed.1002985.t001){ref-type="table"}.

![Study flowchart describing availability for analyses.](pmed.1002985.g001){#pmed.1002985.g001}

10.1371/journal.pmed.1002985.t001

###### Baseline characteristics.

![](pmed.1002985.t001){#pmed.1002985.t001g}

  Characteristic                                        Missing data, *n* (%)   Mean ± SD or *n* (%)
  ----------------------------------------------------- ----------------------- ----------------------
  BMI, kg/m^2^                                          0 (0.0%)                42.2 ± 5.8
  Age, years                                            0 (0.0%)                47.8 ± 10.1
  Sex                                                   0 (0.0%)                
    Female                                                                      5,277 (61.7%)
    Male                                                                        3,269 (38.3%)
  Comorbidity                                                                   
    Sleep apnea                                         0 (0.0%)                1,607 (18.8%)
    Cardiovascular comorbidity                          0 (0.0%)                972 (11.4%)
    Hypertension                                        0 (0.0%)                4,810 (56.3%)
    Dyslipidemia                                        0 (0.0%)                2,679 (31.3%)
    Dyspepsia/gastroesophageal reflux disease           0 (0.0%)                1,087 (12.7%)
    Depression                                          0 (0.0%)                1,405 (16.4%)
    Previous pulmonary embolus/deep venous thrombosis   0 (0.0%)                219 (2.6%)
  Glycosylated hemoglobin A1c, mmol/mol                 1,134 (13.3%)           58.9 ± 17.4
  Education                                             59 (0.7%)               
    Primary education (≤9 years)                                                1,691 (19.9%)
    Secondary education (10--12 years)                                          5,027 (59.2%)
    Higher education ≤3 years                                                   898 (10.6%)
    Higher education \>3 years                                                  871 (10.3%)

Surgical data {#sec014}
-------------

A total of 8,112 patients underwent a gastric bypass procedure (94.9%), and 434 a sleeve gastrectomy (5.1%). A laparoscopic procedure was completed in 8,171 operations (95.6%), 111 operations were converted to open surgery (1.3%), and a primary open procedure was performed in 264 operations (3.1%). The median hospital stay was 2 days (IQR 1--2 days). A postoperative complication (Clavien--Dindo ≥ 1) occurred within 30 days after 863 operations (10.2%). A serious postoperative complication occurred within 30 days after 241 operations (3.5%). Mean BMI loss at 2 years was 11.9 ± 4.6 kg/m^2^, %TWL 28.1% ± 9.2%, and %EBMIL 72.7% ± 24.7%. Mean BMI loss at 5 years was 10.7 ± 4.7 kg/m^2^, %TWL 25.2% ± 9.6%, and %EBMIL 64.4% ± 25.6%.

Impact on diabetes medication {#sec015}
-----------------------------

At baseline, 4,192 patients (49.1%) received oral medical treatment alone for diabetes, 453 received insulin alone (5.3%), 14 received a GLP-1 analogue alone (0.2%), and 1,973 received a combination of oral treatment and insulin (23.1%). The remaining 1,914 patients received non-pharmacological management only for their diabetes (22.5%).

Two years after surgery, 1,990 patients (23.4%) received pharmacological treatment for diabetes: 1,328 received oral medical treatment alone for diabetes (15.6%), 228 received insulin alone (2.7%), 19 received a GLP-1 analogue alone (0.2%), and 415 received a combination of oral treatment and insulin (4.9%).The remaining 6,499 did not receive medical treatment for diabetes 2 years after surgery (76.6%). The chance of being free of diabetes medication was less with longer preoperative duration of diabetes (odds ratio \[OR\] 0.80/year, 95% CI 0.79--0.81, *p \<* 0.001; Spearman coefficient −0.43, *p \<* 0.001) ([Table 2](#pmed.1002985.t002){ref-type="table"} and [Fig 2](#pmed.1002985.g002){ref-type="fig"}).

![Proportion of patients free from medication at 2 and 5 years after surgery.](pmed.1002985.g002){#pmed.1002985.g002}

10.1371/journal.pmed.1002985.t002

###### Numbers free from medical treatment 2 and 5 years after surgery.

![](pmed.1002985.t002){#pmed.1002985.t002g}

  Diabetes duration, years   *n* (%) free from medical treatment at follow-up   
  -------------------------- -------------------------------------------------- ---------------
  \<1                        2,473 (96.1%)                                      1,535 (94.2%)
  1                          899 (86.7%)                                        553 (83.0%)
  2                          674 (82.9%)                                        404 (75.0%)
  3                          549 (75.6%)                                        322 (66.1%)
  4                          437 (74.3%)                                        252 (62.6%)
  5                          407 (69.3%)                                        252 (59.0%)
  6--7                       469 (58.0%)                                        223 (43.0%)
  8--9                       270 (51.5%)                                        95 (34.5%)
  10--12                     187 (44.0%)                                        76 (32.1%)
  13--15                     61 (34.3%)                                         29 (33.0%)
  16--20                     49 (35.8%)                                         17 (22.1%)
  21--25                     21 (32.3%)                                         6 (17.1%)
  ≥26                        3 (10.7%)                                          1 (7.7%)

Five years after surgery, 1,623 patients (30.1%) received pharmacological treatment for diabetes: 1,095 received oral medical treatment alone for diabetes (20.3%), 152 received insulin alone (3.0%), 24 received a GLP-1 analogue alone (0.4%), and 342 received a combination of oral treatment and insulin (6.4%). The remaining 3,765 did not receive medical treatment for diabetes 5 years after surgery (69.9%). As at 2 years, the chance of being free of diabetes medication 5 years after surgery was less with longer preoperative duration of diabetes (OR 0.76/year, 95% CI 0.75--0.78, *p \<* 0.001; Spearman coefficient −0.48, *p \<* 0.001) ([Table 2](#pmed.1002985.t002){ref-type="table"} and [Fig 2](#pmed.1002985.g002){ref-type="fig"}).

Diabetes remission {#sec016}
------------------

Two years after surgery, 2,090 patients had complete remission of their diabetes (58.2%), 429 patients achieved partial remission (11.9%), 428 had controlled diabetes on medication (11.9%), and 647 patients (7.6%) still had a HbA1c ≥ 48 mmol/mol on pharmacological treatment ([Fig 3](#pmed.1002985.g003){ref-type="fig"}). The chance of achieving complete remission was less the longer the preoperative duration of diabetes (OR 0.78/year, 95% CI 0.76--0.79, *p \<* 0.001; Spearman coefficient −0.46, *p \<* 0.001).

![Stacked histogram of 2-year remission in relation to duration of diabetes.](pmed.1002985.g003){#pmed.1002985.g003}

Five years after surgery, 681 patients had complete remission of their diabetes (46.6%), 175 patients had partial remission (12.0%), 188 had controlled diabetes on medication (12.9%), and 416 patients (28.5%) still had a HbA1c \> 48 mmol/mol on pharmacological treatment ([Fig 4](#pmed.1002985.g004){ref-type="fig"}). The chance of achieving complete remission was still less the longer the preoperative duration of diabetes (OR 0.77/year, 95% CI 0.74--0.80, *p \<* 0.001; Spearman coefficient --0.44, *p \<* 0.001).

![Stacked histogram of 5-year remission in relation to duration of diabetes.](pmed.1002985.g004){#pmed.1002985.g004}

Multivariable analysis {#sec017}
----------------------

Of the selected preoperative factors potentially influencing diabetes remission, longer duration of diabetes, higher baseline HbA1c, high age, and insulin treatment were all associated with lower remission rates 2 years after surgery. Higher BMI, higher excess BMI loss, and male sex in patients with T2D were associated with higher remission rates. Higher education and gastric bypass were associated with better chance of achieving diabetes remission in the univariable analyses, but the associations did not remain statistically significant in the multivariable analyses ([Table 3](#pmed.1002985.t003){ref-type="table"}).

10.1371/journal.pmed.1002985.t003

###### Odds ratios (ORs) for reaching complete diabetes remission 2 years after surgery.

![](pmed.1002985.t003){#pmed.1002985.t003g}

   Characteristic                        Unadjusted OR (95% CI)   Adjusted OR (95% CI)^1^   Adjusted *p-*Value[^1^](#t003fn001){ref-type="table-fn"}
  -------------------------------------- ------------------------ ------------------------- ----------------------------------------------------------
  Preoperative diabetes duration         0.78 (0.76--0.79)        0.87 (0.85--0.89)         \<0.001
  Baseline HbA1c                         0.96 (0.95--0.97)        0.98 (0.97--0.98)         \<0.001
  Insulin treatment at baseline          0.15 (0.12--0.16)        0.25 (0.20--0.31)         \<0.001
  Percentage excess BMI loss             1.02 (1.01--1.02)        1.03 (1.02--1.03)         \<0.001
  Age                                    0.94 (0.93--0.95)        0.94 (0.93--0.95)         \<0.001
  Preoperative BMI                       1.06 (1.04--1.07)        1.07 (1.05--1.09)         \<0.001
  Sex                                                                                       
    Female                               Reference                Reference                 Reference
    Male                                 0.89 (0.77--1.02)        1.57 (1.29--1.90)         \<0.001
  Education                                                                                 
    Primary education (≤9 years)         0.77 (0.65--0.92)        0.96 (0.76--1.22)         0.747
    Secondary education (10--12 years)   Reference                Reference                 Reference
    Higher education ≤3 years            1.07 (0.86--1.34)        1.15 (0.86--1.55)         0.353
    Higher education \>3 years           1.27 (1.10--1.60)        1.26 (0.94--1.70)         0.126
  Surgical method                                                                           
    Gastric bypass                       Reference                Reference                 Reference
    Sleeve gastrectomy                   0.64 (0.47--0.88)        0.72 (0.48--1.10)         0.129

^1^Multivariable logistic regression including all factors listed in the table.

Discussion {#sec018}
==========

In the present study, a strong negative correlation between preoperative duration of T2D and the chance of diabetes remission after bariatric surgery was seen. The negative correlation was linear even over very long diabetes duration, supporting the results of previous studies \[[@pmed.1002985.ref009],[@pmed.1002985.ref011]--[@pmed.1002985.ref016]\]. Other factors of importance were insulin treatment and baseline HbA1c as markers of severity of disease, age, sex, and postoperative weight loss.

Remission rate depends on the definition used to define diabetes remission. With the current definition of complete remission, the remission rate in the study cohort was comparable to that reported in previous studies \[[@pmed.1002985.ref009],[@pmed.1002985.ref013]\]. Thus, our results support the already established position of bariatric surgery as an important tool in the treatment of T2D in patients with morbid obesity \[[@pmed.1002985.ref010]\]. However, the benefits of bariatric surgery appear to be greatest amongst patients with more recent onset of T2D and those with less severe disease.

Although the mechanisms behind the metabolic effects of bariatric surgery are complex and incompletely understood, they appear to be mediated by a combination of weight-loss-dependent and -independent factors, resulting in improved insulin sensitivity and improved pancreatic beta-cell function \[[@pmed.1002985.ref024]--[@pmed.1002985.ref027]\]. Patients with longer duration of T2D are more likely to have reduced beta-cell function and secretory capacity. Although this group of patients will still benefit from the reduction in insulin resistance resulting from bariatric surgery, patients with reduced beta-cell function are less likely to achieve complete remission. This hypothesis is supported by the lower remission rates among patients with poorer glycemic control and insulin dependence prior to surgery, as seen in both the present study and previous studies \[[@pmed.1002985.ref012]--[@pmed.1002985.ref014]\]. Although higher preoperative HbA1c does not necessarily correlate to reduced beta-cell function, it indicates poorer glycemic control and greater severity of disease, factors known to reduce the chance of diabetes remission \[[@pmed.1002985.ref012],[@pmed.1002985.ref023]\]. Preoperative insulin treatment, on the other hand, indicates significantly reduced beta-cell function that may not fully respond to the increase in incretin secretion after bariatric surgery. The strong negative correlation between preoperative insulin treatment and chance of achieving complete diabetes remission is well supported by reports from previous studies \[[@pmed.1002985.ref012],[@pmed.1002985.ref015]\].

Age was found to be negatively associated with diabetes remission. Aung et al. also reported a negative correlation between age and the chance of diabetes remission \[[@pmed.1002985.ref014]\]. In their study, patients with late onset of diabetes had a lower chance of durable diabetes remission after bariatric surgery \[[@pmed.1002985.ref014]\]. Furthermore, older patients are known to lose less weight than younger patients after bariatric surgery \[[@pmed.1002985.ref028]\], a factor also associated with reduced chance of achieving complete remission. A combination of a slightly different metabolic profile with poorer weight loss among older patients may well explain the negative association between age and diabetes remission. The influence of sex on diabetes remission is less clear. With the higher proportion of women in the study, it is possible that men with T2D represented a different subgroup than women with T2D due to different fat distribution. Indeed, the fat distribution pattern more often seen in men is strongly related to metabolic complications of obesity \[[@pmed.1002985.ref029]\]. The weight loss after bariatric surgery could thus have higher metabolic impact in patients with male fat distribution.

In the present study, higher preoperative BMI was associated with improved T2D remission rates in the univariable as well as the multivariable analyses. To our knowledge, this has not been reported in previous studies, possibly due to smaller patient numbers. Although no explicit explanation can be provided from the results of this study, it could be that T2D has different characteristics depending on the degree of obesity, where patients with a high BMI have a greater degree of insulin resistance. In patients with a lower BMI, genetic factors and reduced beta-cell function could play a greater role. Furthermore, patients with a high BMI tend to lose more weight after bariatric surgery \[[@pmed.1002985.ref030]\], and thus experience a more significant weight-dependent metabolic effect of surgery.

Consistent with previous studies, gastric bypass appeared to be associated with higher rates of diabetes remission compared to sleeve gastrectomy in the unadjusted analysis \[[@pmed.1002985.ref009],[@pmed.1002985.ref010]\]. Previous studies have reported similar effects on glucose homeostasis and incretin levels when comparing these 2 methods \[[@pmed.1002985.ref031]\]. A plausible explanation may be the difference in postoperative weight loss seen in this and previous studies. However, the present study was not designed to compare the efficacy of the 2 methods, so this result should be viewed with caution. Further randomized trials comparing the effectiveness of the methods are still needed.

Strengths and limitations {#sec019}
-------------------------

Despite the strengths of this study---i.e., the large number of patients, nationwide data, and the high quality of data, allowing estimation of treatment effects for bariatric surgical patients with T2D---there are limitations that must be acknowledged. The major limitation lies in the retrospective nature of the study. By using clinical registries, the study was limited to the variables and definitions already specified by those registries. Some valuable clinical variables, e.g., C-peptide and behavioral patterns, could thus not be included. Furthermore, diabetes remission was defined based on prescribed drugs. Despite reaching adequate glucose control, patients are sometimes encouraged by healthcare providers to continue certain diabetes drugs such as metformin \[[@pmed.1002985.ref032]\]. This would give the impression that medication was still necessary, i.e., no remission, resulting in underestimation of the diabetes remission rate. It is unlikely, however, that this influenced the major outcomes of the present study. Finally, consistent with previous reports, high follow-up rates are difficult to achieve outside of randomized clinical trials \[[@pmed.1002985.ref033]\]. In the present study, HbA1c values were only available for 27% of patients at the 5-year follow-up, limiting analysis of long-term complete remission. However, the patterns of pharmaceutical usage and complete remission were very similar at the 2-year and 5-year follow-ups after surgery, consistent with previous studies.

Conclusion {#sec020}
==========

Remission of T2D after bariatric surgery is negatively correlated to diabetes duration, with the highest rates among patients with more recent onset and less severe disease.

Supporting information {#sec021}
======================
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Abstract

At first read, it was slightly difficult to capture the concept of correlation in the sentence: \"The chance of achieving complete remission correlated...\" since there were both continuous (duration of diabetes, age, Hba1c) and dichotomous variables (insulin treatment) in the analyses. Can this be opened, e.g. by adding units after each OR.

Introduction

Obesity rates are low. Any data available for larger prevalences, which is the case in most countries?

Methods

Nro of patients in each operation type could belong to the methods, however if the authors wish, it can as well remain in the results section as it is now.

Results

A flow chart of the available patients would be useful. The percentages are hard to follow. For example in the sentence \"5388 patients were available for analyses on pharmaceutical use at 5 years (98%)\": What does the 98% represent?

Reviewer \#2: Thanks for the chance to review this manuscript. This study verified that longer T2DM duration, insulin therapy prior to surgery, lower BMI were negative predictors to predict T2DM remission after RYGB/SG with a large sample size and longer follow-up period. Although these data from several registry systems was high-quality, some valuable clinical variables were missing, for instance, fasting C peptide.

Many previous studies have found T2DM duration, C peptide, age, BMI and insulin usage were powerful predictive factors, and thus the novelty of this study is limited. Additionally, during follow-up period, most patients were lost, which affected the credibility of the conclusions.

Reviewer \#3: Due to the imbalanced effects of bariatric surgery on clinically improving metabolic disorders among patients, exploring the factors that affect surgery-induced benefits is quite necessary. In this study, the author provides convincing evidences with large sample size to support his conclusion that the remission of T2DM induced by bariatric surgery is negatively correlated to duration of diabetes and increases in patient with recent onset diabetes and those without insulin treatment. These findings are meaningful for clinician to make decision on treating T2DM by surgery, a treatment that, although effective, cause irreversible changes in patient\'s GI track.

However, as the author mentioned in the manuscript, the retrospective property of this study limits its significance, other variables among subjects such as distinct behaviors during as long as 5 years may also contribute to the uneven diabetic remission rate after surgery, which need to be further and deeply explored. Whereas the high-quality data and large sample size of this study still make it convincible, and it should be eligible to be published in Plos medicine.

Reviewer \#4: I confine my remarks to statistical aspects of this paper. In general, these were fine, although I do wonder why the authors did not do a Cox proportional hazards survival analysis.

Some comments/suggestions:

Line 127-8 I think it would be better to use \"proportion of excess weight\". I am guessing that the people in the study varied a lot in how overweight they were. If a person is 100 kg overweight and another is 200 kg overweight and each loses 100 kg, it does not have the same effect. Maybe there is no good estimate of ideal weight, but even BMI (flawed though that is) could be used.

Table 1 - What about exactly 10 years of education? or exactly3 years of higher education?

Figures - stacked histograms are not a good method (see the work of William S. Cleveland). Line charts would be better with duration on the x axis, percent on the y axis and a line for each outcome.

Peter Flom

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1002985.r002
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23 Oct 2019

Dear Dr. Stenberg,

Thank you very much for re-submitting your manuscript \"Association with duration of type 2 diabetes and remission rates after bariatric surgery in Sweden 2007-2015: a registry-based cohort study\" (PMEDICINE-D-19-02752R1) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Oct 30 2019 11:59PM.

Sincerely,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

Please remove \"association with\" from the start of the title

Abstract "other important factors" -- please be specific in text. In this case, specify or remove;

Author summary -- please remove 'obesity surgery' as I don't think this is an official term, is it?

\- There are some \"p\<0.0001\" in the abstract and results -- please alter to \<0.001, per house style

Line 221 -- "4192 patients received oral treatment" please be specific, of what? And again line 226, please also correct anywhere else in the main text.

\- \"In this study, we found that \... was \...\" at line 58, or similar (and around line 88)

\- I\'d go for \"negatively \[or \"inversely\"\] associated\" rather than \"negatively correlated\"

\- square brackets needed for refs in the main text

Comments from Reviewers:

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1002985.r004
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31 Oct 2019

Dear Dr. Stenberg,

On behalf of my colleagues and the academic editor, Dr. Kirsi H. Pietiläine, I am delighted to inform you that your manuscript entitled \"Duration of type 2 diabetes and remission rates after bariatric surgery in Sweden 2007-2015: a registry-based cohort study\" (PMEDICINE-D-19-02752R2) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

[^1]: I have read the journal\'s policy and the authors of this manuscript have the following competing interests: IN has received consultant fees from Baricol Bariatrics AB, Sweden and Ethicon Endosurgery, Johnson & Johnson for work unrelated to the context of the present study. JO has received consultant fees from Vifor Pharma AB, and Ethicon Endosurgery, Johnson & Johnson for work unrelated to the context of the present study. None of the remaining authors declares any conflict of interest.
